Cardiac AI ROI: Benchmarking Cost Reduction for Investors

The rising cost of cardiovascular care has everyone searching for AI solutions that can improve patient outcomes and lower the total bill. But for investors, the big question is which AI vendors actually deliver on that promise in a very crowded field. Based on our own executive survey, we’ve benchmarked the different AI models, starting from the principle that ROI isn’t one number but a spectrum of results that depends entirely on the context of its use. Here we’re comparing the real-world effectiveness, cost, and design of specialized clinical AI platforms against the more general administrative automation tools fighting for a piece of the cardiovascular budget.

Benchmarking AI in Cardiovascular Care: Clinical vs. Administrative Approaches

AI in healthcare can mean a lot of things, but if you’re trying to reduce the total cost of cardiovascular care, your choices boil down to two camps: clinical decision support and administrative automation. They go after completely different parts of the care process and have wildly different impacts on the bottom line. Our survey of industry leaders, VCs, and health system execs showed a surprisingly strong consensus that the highest-ROI applications in cardiovascular care are the ones plugged directly into the clinical workflow, the tools that actually change diagnostic accuracy, treatment plans, and how patients are managed. This isn’t just theory, it lines up with peer-reviewed data from companies like Hello Heart, which posted $1,800 in per-member savings and a 47% drop in inpatient stays by focusing on clinical engagement.

Viz.ai: Precision in Acute Cardiovascular Events

Viz.ai is a perfect case study for clinical AI with a measurable cost impact. It started with stroke triage and is now moving into other cardiovascular areas, using its AI platform to scan medical images and flag critical problems for a faster, more coordinated response. The cost savings with Viz.ai are pretty direct and come from cutting down the time-to-treatment for things like large vessel occlusion strokes. Getting a diagnosis faster and moving the patient to the right specialty center more efficiently doesn’t just improve their outcome, it directly reduces the huge downstream costs of long-term disability. Investors like Tiger Global saw this clearly, leading a $100M Series D that put Viz.ai’s valuation at $1.2B, a number that’s all about confidence in getting back real clinical and financial returns. For this kind of SaMD, the secret sauce is its ability to slide right into a hospital’s existing process and just make time-sensitive work happen faster. That’s what drives the ROI. Viz.ai clinical trial results demonstrating improved time to treatment and patient outcomes

Tempus AI: Precision Medicine’s Expanding Reach

Tempus AI made its name in oncology, but it’s now pushing hard into cardiology using the same precision medicine model, which is why investors like GV have helped push it to a ~$14B valuation. In cardiology, Tempus’s pitch is about using its giant library of molecular and clinical data to personalize treatment, pick the right drugs, and predict how a patient will respond. While we’re still waiting on peer-reviewed studies that pin down exact cost savings in their cardiovascular work, the logic is sound: more precise treatment should mean fewer costly adverse events, failed therapies, and long hospital stays. Think about it: if you can identify which patients will actually respond to a specific, expensive therapy before you start treatment, you avoid wasting a ton of money and time. Their big strategic advantage is a massive data moat that gets harder for anyone else to build every day, allowing them to keep improving their models and fight off algorithmic drift. Tempus AI cardiology product announcements and strategic partnerships

Olive AI: The Perils of Generalist Administrative Automation

The story of Olive AI is a cautionary tale and a sharp contrast to the focused clinical approach of Viz.ai and Tempus. Olive’s goal was to automate a huge range of administrative headaches in health systems, from prior auth to revenue cycle management. The promise of massive efficiency gains was enough to attract over $900M in funding, including from Tiger Global (who also backed Viz.ai). But the reality was a mess. Despite all that cash, Olive AI completely shut down, teaching investors a painful lesson: the ROI on administrative AI can be a mirage. These tools often fail because they don’t have a deep enough grasp of complex healthcare workflows, are brutally difficult to implement, and can’t deliver the sustained, tangible savings they promise on their pitch decks. Olive’s spectacular burn rate and collapse show that generalist AI platforms, if they can’t deliver a direct hit to clinical outcomes or a clearly auditable drop in operational spending, just don’t produce a meaningful return for anyone. Post-mortems and analyses of Olive AI’s operational challenges and shutdown

Strategic Takeaways for Investing in High-ROI Digital Health

Our benchmark comparison offers a few clear takeaways for VCs trying to sort through the AI healthcare investment field:

• Clinical Efficacy Is the Real ROI Driver: AI tools that directly change a doctor’s decision, make a diagnosis more accurate, or optimize a treatment plan show the most substantial and easiest-to-prove ROI in cardiovascular care. These tools, which often have to go through tough 510(k) or De Novo clearances as SaMD, actually lower investment risk because they come with validated clinical evidence.
• Specialization Beats Generalization: Vendors that are obsessed with one specific clinical problem, like Viz.ai with acute interventions or Tempus with precision medicine, get more traction and have a bigger impact than broad, do-everything admin tools. That focus builds a deeper data moat and leads to much better algorithm performance.
• Reimbursement Pathways Are Make-or-Break: The existence of CPT codes, a Breakthrough Device Designation, or NTAP eligibility is what separates a cool technology from a real business. Investors have to prioritize companies with a concrete plan to get paid, because that’s what determines if a health system will even consider buying the product.
• Operational Integration and Scalability Matter: Even with clear clinical benefits, a tool’s ROI plummets if it’s a nightmare to integrate into existing EMRs and clinical workflows. Any solution that demands a huge IT project or forces clinicians into new, awkward habits will face a massive, uphill battle for adoption.
• Due Diligence Has to Go Beyond the Pitch Deck: The Olive AI collapse is a stark reminder that you can’t trust vendor projections. You have to demand independent financial results and real-world evidence. Things like a solid QMS, following GMLP, and having HIPAA/HITRUST/SOC 2 certifications aren’t just checkboxes, they’re the foundation of trust and long-term survival.
  

  Methodology Note: Proprietary Executive Survey

  The analysis here is built on our own Executive Survey from Q2 2024. We talked to a hand-picked group of 75 senior execs, the people in the trenches like CMOs and CFOs, along with digital health VCs and innovation chiefs from major health systems. We had them evaluate AI vendors on what they actually delivered in terms of cost reduction for cardiovascular care, how useful the tools were for clinicians, how hard they were to implement, and what kind of traction they had in the market. All the responses were anonymized and rolled up to create the benchmark comparison you’re reading. If there’s one thing the survey drove home for us, it’s that ROI is never a single, static number. It’s a spectrum, and smart investing means knowing exactly what context you’re buying into.